Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin for prevention of SIRS after PCNL surgery in non-diabetic adults
IRCT20190624043991N43Phase 3Not yet recruiting
- Sponsor
- Tehran University of Medical Sciences
- Start
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in Systemic Inflammatory Response Syndrome (SIRS) comparing Metformin with Placebo (2 arms). Primary endpoint: Incidence of systemic inflammatory response syndrome. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
metformin
03
Conditions
Systemic Inflammatory Response Syndrome (SIRS)
Beyond the preview
Go deeper on IRCT20190624043991N43.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190624043991N43.